drugset / Trial / NCT02918266
TAK-071 Scopolamine-Induced Cognitive Impairment Study
RandomizedCrossoverDouble-blindBasic science
Summary
The purpose of this study is to assess the effect of a single oral dose of TAK-071 on the attenuation of cognitive deficit induced by scopolamine as measured by Groton Maze Learning Test (GMLT) (total number of errors).
Timeline
- Start
- 2016-11-21
- Primary completion
- 2017-08-02
- Completion
- 2017-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donepezil | Small molecule | 10 mg | Oral |
| Subject | Scopolamine | Unknown | 0.5 mg | Subcutaneous |
| Subject | TAK-071 | Small molecule | 80 mg | Oral |
Indications
No indication recorded.